RESUMEN

Contrast-induced nephropathy (CIN) is a common complication with adverse outcome after iodinated-contrast injection, yet still lacking effective medication. Heme oxygenase-1 (HO-1) has been reported to play an important role against renal injuries. Hemin, a HO-1 inducer and anti-porphyria medicine, may have a promising effect against CIN. In this study, we aim to investigate the effect of hemin on CIN model and the underlying molecular mechanisms in human proximal tubule epithelial cells (HK-2). To mimic a common condition in percutaneous coronary intervention (PCI) patients, CIN was induced by intravenous iopromide in high-fat fed diabetic rats. We found hemin, given right before iopromide, mitigated CIN with enhanced antioxidative capacity and reduced oxidative stress. HK-2 cells insulted by iopromide demonstrated decreased cell vitality and rising reactive oxygen species (ROS), which could also be inhibited by hemin. The effects of hemin involved a key molecule in ferroptosis, glutathione peroxidase (GPX4), whose down-expression by small interfering RNA (siRNA) reversed the effect of hemin on HK-2 cells. Furthermore, hemin's induction of GPX4 involved HO-1 and nuclear factor erythroid 2-related factor 2 (Nrf2). Either HO-1 or Nrf2 inhibitor prevented hemin's effect on GPX4 to a comparable extent, and over-expression of Nrf2 increased GPX4 expression. Moreover, intervention of ferroptosis inhibitor liproxstatin-1 also alleviated CIN in vivo. Therefore, we showed hemin mitigated CIN, inhibiting oxidative stress and ferroptosis, by upregulation of GPX4 via activation of HO-1/Nrf2. Hemin, as a clinical medicine, has a translational significance in treating CIN, and anti-ferroptosis is a potential therapeutic strategy for CIN.

Asunto(s)

Medios de Contraste , Células Epiteliales , Ferroptosis , Fármacos Hematológicos , Hemina , Enfermedades Renales , Animales , Células Cultivadas , Medios de Contraste/efectos adversos , Diabetes Mellitus Experimental/etiología , Modelos Animales de Enfermedad , Células Epiteliales/efectos de los fármacos , Células Epiteliales/fisiología , Ferroptosis/efectos de los fármacos , Glutatión Peroxidasa/metabolismo , Fármacos Hematológicos/farmacología , Hemo-Oxigenasa 1/metabolismo , Hemina/farmacología , Humanos , Enfermedades Renales/inducido químicamente , Enfermedades Renales/tratamiento farmacológico , Enfermedades Renales/metabolismo , Enfermedades Renales/prevención & control , Túbulos Renales Proximales/efectos de los fármacos , Túbulos Renales Proximales/fisiopatología , Factor 2 Relacionado con NF-E2/metabolismo , Intervención Coronaria Percutánea , Fosfolípido Hidroperóxido Glutatión Peroxidasa/metabolismo , ARN Interferente Pequeño/genética , Ratas , Transducción de Señal

RESUMEN

Therapeutic agents that increase the Hb affinity for oxygen (O2) could, in theory, lead to decreased O2 release from Hb and impose a hypoxic risk to tissues. In this study, GBT1118, an allosteric modifier of Hb affinity for O2, was used to assess the impact of increasing Hb affinity for O2 on brain tissue oxygenation, blood pressure, heart rate, O2 delivery, and tolerance to hypoxia in Townes transgenic sickle cell disease (SCD) mice. Brain oxygenation and O2 delivery were studied during normoxia and severe hypoxic challenges. Chronic treatment with GBT1118 increased Hb affinity for O2, reducing the Po2 for 50% HbO2 saturation (P50) in SCD mice from 31 mmHg to 18 mmHg. This treatment significantly reduced anemia, increasing hematocrit by 33%, improved cardiac output (CO), and O2 delivery and extraction. Chronically increasing Hb affinity for O2 with GBT1118 preserved cortical O2 tension during normoxia, improved cortical O2 tension during hypoxia, and increased tolerance to severe hypoxia in SCD mice. Independent of hematological changes induced by chronic treatment, a single dose of GBT1118 significantly improved tolerance to hypoxia, highlighting the benefits of increasing Hb affinity for O2 and consequently reducing sickling of RBCs in blood during hypoxia in SCD.NEW & NOTEWORTHY Chronic pharmacologically increased hemoglobin affinity for oxygen in sickle cell disease mice alleviated hematological consequences of sickle cell disease, increasing RBC half-life, hematocrit, and hemoglobin concentration, while also decreasing reticulocyte count. Additionally, chronically increased hemoglobin affinity for oxygen significantly improved survival as well as cortical tissue oxygenation in sickle cell disease mice during hypoxia, suggesting that oxygen delivery and utilization is improved by increased hemoglobin affinity for oxygen.

Asunto(s)

Anemia de Células Falciformes/metabolismo , Benzaldehídos/farmacología , Corteza Cerebral/metabolismo , Eritrocitos/efectos de los fármacos , Fármacos Hematológicos/farmacología , Hemoglobina Falciforme/efectos de los fármacos , Hipoxia/metabolismo , Niacinamida/análogos & derivados , Oxígeno/metabolismo , Regulación Alostérica , Animales , Encéfalo/metabolismo , Modelos Animales de Enfermedad , Hematócrito , Hemoglobina Falciforme/metabolismo , Ratones , Ratones Transgénicos , Niacinamida/farmacología , Presión Parcial

RESUMEN

PURPOSE: The purpose of this study was to evaluate mobilization outcomes with biosimilar pegfilgrastim versus filgrastim in association with chemotherapy as a mobilization strategy for lymphoma patients. METHODS: In the current study we included 32 lymphoma patients that received mobilization therapy and PBSC harvesting at the Bone Marrow Transplantation Department of Fundeni Clinical Institute, Bucharest, Romania between January and December 2019. RESULTS: Pegfilgrastim had beneficial effect when compared to filgrastim in reducing grade IV neutropenia both in the univariate and multivariate logistic models. Additionally, similar efficacy, as mobilization rate, after both filgrastim and pegfilgrastim was observed and no differences were noted between the two groups considering the need for platelet or red blood cell support. CONCLUSION: The use of biosimilar pegfilgrastim is a viable alternative to filgrastim in PBSC mobilization for lymphoma patients.

Asunto(s)

Filgrastim/farmacología , Filgrastim/uso terapéutico , Fármacos Hematológicos/farmacología , Fármacos Hematológicos/uso terapéutico , Movilización de Célula Madre Hematopoyética , Linfoma/tratamiento farmacológico , Células Madre de Sangre Periférica/efectos de los fármacos , Polietilenglicoles/farmacología , Polietilenglicoles/uso terapéutico , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos

RESUMEN

A circulatory model of granulopoiesis and its regulation is presented that includes neutrophil trafficking in the lungs, liver, spleen, bone marrow, lymph nodes, and blood. In each organ, neutrophils undergo transendothelial migration from vascular to interstitial space, clearance due to apoptosis, and recycling via the lymphatic flow. The model includes cell cycling of progenitor cells in the bone marrow, granulocyte colony-stimulating factor (G-CSF) kinetics and its neutrophil regulatory action, as well as neutrophil margination in the blood. From previously reported studies, 111 In-labeled neutrophil kinetic data in the blood and sampled organs were used to estimate the organ trafficking parameters in the model. The model was further developed and evaluated using absolute neutrophil count (ANC), band cell, and segmented neutrophil time course data from healthy volunteers following four dose levels of pegfilgrastim (r2  = 0.77-0.99), along with ANC time course responses following filgrastim (r2  = 0.96). The baseline values of various cell types in bone marrow and blood, as well as G-CSF concentration in the blood, predicted by the model are consistent with available literature reports. After incorporating the mechanism of action of both paclitaxel and carboplatin, as determined from an in vitro bone marrow studies, the model reliably predicted the observed ANC time course following paclitaxel plus carboplatin observed in a phase I trial of 46 patients (r2  = 0.70). The circulatory neutrophil model may provide a mechanistic framework for predicting multi-organ neutrophil homeostasis and dynamics in response to therapeutic agents that target neutrophil dynamics and trafficking in different organs.

Asunto(s)

Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Filgrastim/farmacología , Modelos Biológicos , Neutropenia/inducido químicamente , Polietilenglicoles/farmacología , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Carboplatino/administración & dosificación , Carboplatino/efectos adversos , Ensayos Clínicos Fase I como Asunto , Factor Estimulante de Colonias de Granulocitos/metabolismo , Fármacos Hematológicos/farmacología , Hematopoyesis/efectos de los fármacos , Humanos , Recuento de Leucocitos , Neutrófilos/citología , Paclitaxel/administración & dosificación , Paclitaxel/efectos adversos

RESUMEN

This study aimed to compare the pharmacokinetic, pharmacodynamic, and safety profiles of a proposed biosimilar and innovator filgrastim therapeutics in healthy volunteers. In a crossover design, 23 subjects received a single subcutaneous injection of 300-µg filgrastim, followed by a 7-day washout period. Assessed pharmacokinetic parameters were the maximum observed filgrastim serum concentration (Cmax ), time to reach Cmax (tmax ), the area under the concentration-time curve (AUC), and elimination half-life. Pharmacodynamics were assessed by the maximum observed absolute neutrophil count effect (Emax ), tmax,E (time to reach Emax ), and the area under the effect of the absolute neutrophil count -time curve. The test/reference ratio (90% confidence intervals) of Cmax of 0.992 (0.860-1.143), AUC0-inf of 0.995 (0.891-1.111), Emax of 0.952 (0.841, 1.078), and area under the effect of the absolute neutrophil count -time curve from time zero to 96 hours of 0.939 (0.854-1.032), were all well within the predefined equivalence boundaries of 80% and 125%. Obtained values for tmax (∼4 hours), tmax,E (∼15 hours), and elimination half-life (∼3.5 hours) were comparable between 2 treatment groups. The local tolerability and incidence of adverse events were comparable, with no clinically meaningful difference between biosimilar and innovator products. Altogether, the results suggested a high similarity of the proposed biosimilar to the innovator filgrastim in healthy volunteers.

Asunto(s)

Biosimilares Farmacéuticos/administración & dosificación , Filgrastim/administración & dosificación , Fármacos Hematológicos/administración & dosificación , Adulto , Área Bajo la Curva , Biosimilares Farmacéuticos/farmacocinética , Biosimilares Farmacéuticos/farmacología , Estudios Cruzados , Filgrastim/farmacocinética , Filgrastim/farmacología , Semivida , Fármacos Hematológicos/farmacocinética , Fármacos Hematológicos/farmacología , Humanos , Inyecciones Subcutáneas , Masculino , Neutrófilos/citología , Adulto Joven

RESUMEN

Marine resources are today a renewable source of various compounds, such as polysaccharides, that are used in the pharmaceutical, medical, cosmetic, and food fields. In recent years, considerable attention has been focused on carrageenan-based biomaterials due to their multifunctional qualities, including biodegradability, biocompatibility, and non-toxicity, in addition to bioactive attributes, such as their antiviral, antibacterial, antihyperlipidemic, anticoagulant, antioxidant, antitumor, and immunomodulating properties. They have been applied in pharmaceutical formulations as both their bioactive and physicochemical properties make them suitable biomaterials for drug delivery, and recently for the development of tissue engineering. This article provides a review of recent research on the various types of carrageenan-based biomedical and pharmaceutical applications.

Asunto(s)

Carragenina/química , Carragenina/farmacología , Portadores de Fármacos , Animales , Antiinfecciosos/química , Antiinfecciosos/farmacología , Antineoplásicos/química , Antineoplásicos/farmacología , Antioxidantes/química , Antioxidantes/farmacología , Composición de Medicamentos , Fármacos Hematológicos/química , Fármacos Hematológicos/farmacología , Humanos , Hipolipemiantes/química , Hipolipemiantes/farmacología , Factores Inmunológicos/química , Factores Inmunológicos/farmacología , Estructura Molecular , Relación Estructura-Actividad

RESUMEN

PURPOSE: Granulocyte colony stimulating factor (GCSF; also known as filgrastim) is a growth factor used to induce production of granulocytes. As the first locally developed and approved biosimilar medicine of Turkey, Fraven® being a biosimilar of filgrastim has been ab initio manufactured from cell to finished product at two different production facilities. Comprehensive structural, biological and functional characterization studies were performed to compare Fraven® from two different production sites and its reference product Neupogen® sourced from Turkey. METHODS: Primary and higher-order protein structures were analyzed by high performance liquid chromatography electrospray ionization-time of flight mass spectrometry, circular dichroism, and two-dimensional nuclear magnetic resonance spectroscopy. Isoelectric focusing, SDS-Page, size exclusion chromatography, and related proteins analyses were used to compare impurities. In order to assess functional similarity, surface plasmon resonance (SPR) was used. In vitro cell proliferation assay was also performed to show dose related drug response in NFS-60 cell line. RESULTS: Primary, secondary and tertiary structures of biosimilar Fraven® manufactured at both sites were found to be highly similar to the reference Neupogen®. Product related substances and impurities were also highly similar to the reference. Comparability of GCSF receptor binding affinities of each product was shown using the KD values of SPR analysis. In vitro cell proliferation similarity was also evaluated and proven by PLA. CONCLUSION: Based on the similarity assessment, despite being manufactured at two different production sites, biosimilar Fraven® is highly similar to the reference product Turkey originated Neupogen®.

Asunto(s)

Biosimilares Farmacéuticos/farmacología , Proliferación Celular/efectos de los fármacos , Filgrastim/farmacología , Fármacos Hematológicos/farmacología , Receptores de Factor Estimulante de Colonias de Granulocito/agonistas , Animales , Biosimilares Farmacéuticos/química , Línea Celular Tumoral , Relación Dosis-Respuesta a Droga , Filgrastim/química , Fármacos Hematológicos/química , Ratones , Conformación Proteica , Receptores de Factor Estimulante de Colonias de Granulocito/metabolismo , Relación Estructura-Actividad , Equivalencia Terapéutica

RESUMEN

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has brought many unique pathologies, such as coagulopathy, prompting a desperate need for effective management. COVID-19-associated coagulopathy (CAC) can cause various thromboembolic complications, especially in critically ill patients. The pathogenesis is likely due to endothelial injury, immobilization, and an increase in circulating prothrombotic factors. Data on treatment are limited, although prophylactic anticoagulation is advised in all hospitalized patients. Herein, we have comprehensively reviewed the current literature available on CAC and highlight the pathogenesis, clinical features, and management of CAC.

Asunto(s)

Trastornos de la Coagulación Sanguínea , Quimioprevención/métodos , Infecciones por Coronavirus , Fármacos Hematológicos/farmacología , Pandemias , Neumonía Viral , Trombofilia , Betacoronavirus/fisiología , Trastornos de la Coagulación Sanguínea/etiología , Trastornos de la Coagulación Sanguínea/fisiopatología , Trastornos de la Coagulación Sanguínea/prevención & control , COVID-19 , Infecciones por Coronavirus/sangre , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/terapia , Humanos , Neumonía Viral/sangre , Neumonía Viral/epidemiología , Neumonía Viral/terapia , SARS-CoV-2 , Trombofilia/tratamiento farmacológico , Trombofilia/virología

RESUMEN

The objective of this proof-of-concept study was to demonstrate the targeted delivery of erythropoietin (EPO) using magnetically guided magnetic nanoparticles (MNPs).MNPs consisting of a ferric-ferrous mixture (FeCl3·6H2O and FeCl2·4H2O) were prepared using a co-precipitation method. The drug delivery system (DDS) was manufactured via the spray-drying technique using a nanospray-dryer. The DDS comprised 7.5 mg sodium alginate, 150 mg MNPs, and 1000 IU EPO.Scanning electron microscopy revealed DDS particles no more than 500 nm in size. Tiny particles on the rough surfaces of the DDS particles were composed of MNPs and/or EPO, unlike the smooth surfaces of the only alginate particles. Transmission electron microscopy showed the tiny particles from 5 to 20 nm in diameter. Fourier-transform infrared spectroscopy revealed DDS peaks characteristic of MNPs as well as of alginate. Thermal gravimetric analysis presented that 50% of DDS weight was lost in a single step around 500°C. The mode size of the DDS particles was approximately 850 nm under in vivo conditions. Standard soft lithography was applied to DDS particles prepared with fluorescent beads using a microchannel fabricated to have one inlet and two outlets in a Y-shape. The fluorescent DDS particles reached only one outlet reservoir in the presence of a neodymium magnet. The neurotoxicity was evaluated by treating SH-SY5Y cells in 48-well plates (1 × 10 cells/well) with 2 µL of a solution containing sodium alginate (0.075 mg/mL), MNPs (1.5 mg/mL), or sodium alginate + MNPs. A cell viability assay kit was used to identify a 93% cell viability after MNP treatment and a 94% viability after sodium alginate + MNP treatment, compared with the control. As for the DDS particle neurotoxicity, a 95% cell viability was noticed after alginate-encapsulated MNPs treatment and a 93% cell viability after DDS treatment, compared with the control.The DDS-EPO construct developed here can be small under in vivo conditions enough to pass through the lung capillaries with showing the high coating efficiency. It can be guided using magnetic control without displaying significant neurotoxicity in the form of solution or particles.

Asunto(s)

Portadores de Fármacos/farmacología , Sistemas de Liberación de Medicamentos/métodos , Eritropoyetina/farmacología , Nanopartículas de Magnetita , Materiales Biocompatibles Revestidos/farmacología , Medios de Contraste , Fármacos Hematológicos/farmacología , Humanos , Nanopartículas de Magnetita/química , Nanopartículas de Magnetita/uso terapéutico , Ensayo de Materiales , Microscopía Electrónica de Rastreo/métodos , Tamaño de la Partícula , Propiedades de Superficie , Traumatismos del Sistema Nervioso/terapia

RESUMEN

Sickle cell disease is an inherited disorder that affects more than 100,000 individuals in the United States and results in a shortened life span. Characterized by the production of abnormal, sickle-shaped hemoglobin, the disease is marked by anemia, vaso-occlusion of blood vessels, and tissue damage. In November 2019, the U.S. Food and Drug Administration approved voxelotor (Oxbryta) as a novel treatment for sickle cell disease. Voxelotor inhibits the production of sickle hemoglobin and improves anemia. This article presents an overview of voxelotor, including adverse effects, use in special populations, and implications for nursing practice.

Asunto(s)

Anemia de Células Falciformes/tratamiento farmacológico , Benzaldehídos/uso terapéutico , Pirazinas/uso terapéutico , Pirazoles/uso terapéutico , Benzaldehídos/farmacología , Fármacos Hematológicos/farmacología , Fármacos Hematológicos/uso terapéutico , Humanos , Pirazinas/farmacología , Pirazoles/farmacología

RESUMEN

The management of thrombosis and bacterial infection is critical to ensure the functionality of medical devices. While administration of anticoagulants is the current antithrombotic clinical practice, a variety of complications, such as uncontrolled hemorrhages or heparin-induced thrombocytopenia, can occur. Additionally, infection rates remain a costly and deadly complication associated with use of these medical devices. It has been hypothesized that if a synthetic surface could mimic the biochemical mechanisms of the endothelium of blood vessels, thrombosis could be reduced, anticoagulant use could be avoided, and infection could be prevented. Herein, the interfacial biochemical effects of the endothelium were mimicked by altering the surface of medical grade silicone rubber (SR). Surface modification was accomplished via heparin surface immobilization (Hep) and the inclusion of a nitric oxide (NO) donor into the SR polymeric matrix to achieve synergistic effects (Hep-NO-SR). An in vitro bacteria adhesion study revealed that Hep-NO-SR exhibited a 99.46 ± 0.17% reduction in viable bacteria adhesion compared to SR. An in vitro platelet study revealed Hep-NO-SR reduced platelet adhesion by 84.12 ± 6.19% compared to SR, while not generating a cytotoxic response against fibroblast cells. In a 4 h extracorporeal circuit model without systemic anticoagulation, all Hep-NO-SR samples were able to maintain baseline platelet count and device patency; whereas 66% of SR samples clotted within the first 2 h of study. Results indicate that Hep-NO-SR creates a more hemocompatible and antibacterial surface by mimicking two key biochemical functions of the native endothelium.

Asunto(s)

Materiales Biomiméticos/química , Fármacos Hematológicos/uso terapéutico , Heparina/uso terapéutico , Donantes de Óxido Nítrico/uso terapéutico , S-Nitroso-N-Acetilpenicilamina/uso terapéutico , Animales , Adhesión Bacteriana/efectos de los fármacos , Materiales Biomiméticos/toxicidad , Coagulación Sanguínea/efectos de los fármacos , Plaquetas/metabolismo , Materiales Biocompatibles Revestidos/química , Materiales Biocompatibles Revestidos/toxicidad , Endotelio/química , Fármacos Hematológicos/farmacología , Fármacos Hematológicos/toxicidad , Heparina/farmacología , Heparina/toxicidad , Proteínas Inmovilizadas/farmacología , Proteínas Inmovilizadas/uso terapéutico , Proteínas Inmovilizadas/toxicidad , Ratones , Óxido Nítrico/metabolismo , Donantes de Óxido Nítrico/farmacología , Donantes de Óxido Nítrico/toxicidad , Adhesividad Plaquetaria/efectos de los fármacos , Conejos , S-Nitroso-N-Acetilpenicilamina/farmacología , S-Nitroso-N-Acetilpenicilamina/toxicidad , Elastómeros de Silicona/química , Elastómeros de Silicona/toxicidad , Staphylococcus aureus/efectos de los fármacos , Propiedades de Superficie

RESUMEN

Voxelotor, a sickle hemoglobin polymerization inhibitor, was approved by the U.S. Food and Drug Administration to treat sickle cell disease (SCD) in November 2019. This article reviews published data about voxelotor treatment of SCD based on a search of MEDLINE, Embase, and International Pharmaceutical Abstracts. In a phase I/II trial, voxelotor demonstrated a dose-dependent pharmacokinetic and pharmacodynamic response and was well tolerated in healthy volunteers and patients with SCD. In a multi-center, randomized, double-blind, phase III trial (HOPE trial), a significantly higher percentage of patients randomized to voxelotor had increased hemoglobin (> 1 g/dl from baseline) compared to placebo. A greater reduction of hemolytic markers was also observed in the voxelotor-treated group, whereas the incidence of adverse effects was comparable. Three case series or reports also demonstrated the efficacy and safety of voxelotor use in a limited number of SCD patients in the real-world situation, although one patient with SCD, severe anemia, and a history of autoantibody-mediated hemolysis failed to respond to voxelotor. An ongoing trial (HOPE-KIDS) is designed to establish the use of voxelotor in younger pediatric patients with SCD. There is a theoretical concern that voxelotor may impair oxygen delivery, due to modification of the oxygen affinity of hemoglobin, which needs to be further evaluated. As a first-in-class hemoglobin modulator, voxelotor offers a new treatment option targeting the root cause of SCD.

Asunto(s)

Anemia de Células Falciformes/tratamiento farmacológico , Benzaldehídos/administración & dosificación , Hemoglobina Falciforme/efectos de los fármacos , Pirazinas/administración & dosificación , Pirazoles/administración & dosificación , Anemia de Células Falciformes/fisiopatología , Benzaldehídos/efectos adversos , Benzaldehídos/farmacología , Biomarcadores/metabolismo , Relación Dosis-Respuesta a Droga , Fármacos Hematológicos/administración & dosificación , Fármacos Hematológicos/efectos adversos , Fármacos Hematológicos/farmacología , Hemoglobina Falciforme/metabolismo , Humanos , Polimerizacion/efectos de los fármacos , Pirazinas/efectos adversos , Pirazinas/farmacología , Pirazoles/efectos adversos , Pirazoles/farmacología , Ensayos Clínicos Controlados Aleatorios como Asunto

Asunto(s)

Anemia de Células Falciformes/tratamiento farmacológico , Anticuerpos Monoclonales Humanizados/uso terapéutico , Antidrepanocíticos/uso terapéutico , Benzaldehídos/uso terapéutico , Pirazinas/uso terapéutico , Pirazoles/uso terapéutico , Anemia de Células Falciformes/fisiopatología , Anticuerpos Monoclonales Humanizados/efectos adversos , Anticuerpos Monoclonales Humanizados/farmacología , Antidrepanocíticos/efectos adversos , Antidrepanocíticos/farmacología , Benzaldehídos/efectos adversos , Benzaldehídos/farmacología , Fármacos Hematológicos/efectos adversos , Fármacos Hematológicos/farmacología , Fármacos Hematológicos/uso terapéutico , Humanos , Pirazinas/efectos adversos , Pirazinas/farmacología , Pirazoles/efectos adversos , Pirazoles/farmacología

RESUMEN

Voxelotor (Oxbryta™) is a haemoglobin S polymerization inhibitor that has been developed for the treatment of sickle cell disease. In November 2019, voxelotor received its first global approval in the USA for the treatment of sickle cell disease in adults and paediatric patients aged ≥ 12 years. The drug was granted accelerated approval based on the results of the phase III HOPE trial. Phase III clinical development of voxelotor for sickle cell disease is ongoing worldwide. Voxelotor also has Orphan Drug designation and Priority Medicine status in Europe for the treatment of sickle cell disease. This article summarizes the milestones in the development of voxelotor leading to this first approval as a disease-modifying agent for sickle cell disease.

Asunto(s)

Benzaldehídos/farmacología , Aprobación de Drogas , Fármacos Hematológicos/farmacología , Hemoglobina Falciforme/antagonistas & inhibidores , Pirazinas/farmacología , Pirazoles/farmacología , Ensayos Clínicos Fase III como Asunto , Hemoglobina Falciforme/metabolismo , Humanos , Polimerizacion/efectos de los fármacos

RESUMEN

BACKGROUND: Donor factors have a variable correlation with cluster of differentiation (CD)34+ cell dose in allogeneic peripheral blood stem cell (PBSC) harvests. CD34+ cell dose affects the speed of hematopoietic recovery and percentage of donor chimerism in the recipient. METHODS: A total of 25 allogeneic PBSC transplants performed during a 3-year period were included. All donors underwent mobilization with filgrastim. Leukapheresis, flowcytometric CD34+ cell enumeration, and chimerism analysis were performed and correlated with recipient outcome. RESULTS: Besides age, all other donor parameters had a positive correlation with CD34+ cell count. Engraftment kinetics and chimerism had a positive correlation with the CD34+ yield of the PBSC product. Acute graft-vs-host disease (GVHD) was observed in patients with complete chimerism at day 30 after transplantation. CONCLUSION: Adequate CD34+ cell yield happens in healthy donors, independent of donor demographic patterns with G-CSF only. A diverse population of donors can thus be approached for Matched Unrelated Donor (MUD) transplants. An accurate quantitative analysis of early donor chimerism in the recipient (at day 30) is an excellent tool for post-transplant monitoring for acute GvHD.

Asunto(s)

Donantes de Sangre/estadística & datos numéricos , Enfermedad Injerto contra Huésped/epidemiología , Trasplante de Células Madre de Sangre Periférica/efectos adversos , Factores de Edad , Antígenos CD34/genética , Antígenos CD34/metabolismo , Filgrastim/farmacología , Factor Estimulante de Colonias de Granulocitos/metabolismo , Fármacos Hematológicos/farmacología , Humanos , Trasplante de Células Madre de Sangre Periférica/métodos , Trasplante de Células Madre de Sangre Periférica/estadística & datos numéricos , Células Madre de Sangre Periférica/efectos de los fármacos , Células Madre de Sangre Periférica/metabolismo , Trasplante Homólogo

RESUMEN

Myelosuppression or bone marrow suppression is one of the most common side effects caused by anti-cancer drugs. Certain nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics and viruses like B19 virus can also cause bone marrow suppression resulting in serious consequences like leukopenia, anemia and thrombocytopenia. Currently, it is mainly treated by Filgrastim, use of which is not without side effects. Certain natural drugs can be a safer alternative to treat myelosuppression. Azadirachta indica, commonly known as Neem, is an important medicinal plant of subcontinent. Keeping in view the traditional uses of Neem, present study aims to investigate its potential role in reversing myelosuppression. Albino rats were used to determine hematopoietic activity of Neem leaves after inducing myelosuppression by cyclophosphamide given subcutaneously. Filgrastim was used as reference standard to compare the antimyelosuppressant activity of the drug. The drug was evaluated in three doses i.e. 50mg/kg, 100mg/kg and 200mg/kg body weight, while blood samples were drawn on 0, 1st, 7th, 14th and 21st day. The drug was found to be effective in reversing bone marrow suppression in all three doses based on the hematological parameters (mean WBC, RBC, platelets, Hb, Hct etc.) which improved significantly. The results suggest that the drug can be used as antimyelosuppressant after establishing its safety and identifying its active constituents with their mechanism of action.

Asunto(s)

Azadirachta , Enfermedades de la Médula Ósea , Médula Ósea , Fármacos Hematológicos , Hematopoyesis , Extractos Vegetales , Animales , Azadirachta/química , Médula Ósea/efectos de los fármacos , Médula Ósea/metabolismo , Enfermedades de la Médula Ósea/inducido químicamente , Enfermedades de la Médula Ósea/tratamiento farmacológico , Enfermedades de la Médula Ósea/metabolismo , Ciclofosfamida , Modelos Animales de Enfermedad , Filgrastim/farmacología , Fármacos Hematológicos/aislamiento & purificación , Fármacos Hematológicos/farmacología , Hematopoyesis/efectos de los fármacos , Metanol/química , Extractos Vegetales/aislamiento & purificación , Extractos Vegetales/farmacología , Hojas de la Planta , Solventes/química , Ratas

Asunto(s)

Anemia de Células Falciformes/tratamiento farmacológico , Benzaldehídos/farmacología , Fármacos Hematológicos/farmacología , Pirazinas/farmacología , Pirazoles/farmacología , Biomarcadores , Aprobación de Drogas , Hemoglobinas/química , Humanos , Terapia Molecular Dirigida , Estados Unidos , United States Food and Drug Administration

RESUMEN

The protective role of α-tocopherol succinate (α-TCS) and the therapeutic efficacy of filgrastim were investigated in gastrointestinal acute radiation syndrome (GI-ARS) induced following 10 Gy whole-body γ-irradiation. Mice were randomly allocated into 5 groups: [1] normal-control, [2] irradiated-control, [3] subcutaneous (s.c.) injection of filgrastim (5 µg/kg/day) for 4 consecutive days given 1 h post-irradiation, [4] s.c. injection with α-TCS (400 mg/kg) 1 day prior to irradiation, [5] s.c. injection with α-TCS (400 mg/kg) 1 day prior to irradiation and filgrastim (5 µg/kg/day) for 4 consecutive days 1 h post-irradiation. Histopathological analysis, serum citrulline level, intestinal interleukin-1ß (IL-1ß), reduced glutathione (GSH), and malondialdehyde (MDA) contents as well as myeloperoxidase (MPO) activity were measured. Intestinal caspase-3, p53, cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS) immunopositivity were examined. In irradiated-control, MDA increased (249%) and GSH decreased (25%) compared to normal and were unaffected by filgrastim. α-TCS alone significantly reduced MDA (84.5%) and normalized GSH. The combination significantly reduced MDA (59%) and dramatically increased GSH (1573%), pointing to a possible synergistic action. In irradiated-control, MPO and IL-1ß significantly increased (111% and 613%, respectively) compared to normal-control and both were significantly decreased in all treated groups. Compared to normal-control, citrulline significantly declined (68%) in irradiated-control; a significant elevation was achieved by treatments with α-TCS alone or combined with filgrastim (88% and 94%, respectively). The combination therapy significantly decreased the degree of irradiation-induced injury of the epithelium and cellular infiltration and showed the lowest histopathological scoring compared to the other groups (p ≤ 0.05). In irradiated-control, immune-reactive expressions of iNOS, COX-2, caspase-3, and p53 were remarkable (18.62%, 34.27%, 31.19%, and 27.44%, respectively) and after combination therapy were reduced (1.04%, 22.39%, 8.76%, and 4.91%, respectively). The current findings represent a first-hand strategy in dealing with GI-ARS with a potential preference to using a combined therapy of filgrastim and α-TCS.

Asunto(s)

Síndrome de Radiación Aguda/tratamiento farmacológico , Antioxidantes/uso terapéutico , Filgrastim/uso terapéutico , Tracto Gastrointestinal/efectos de los fármacos , Tracto Gastrointestinal/efectos de la radiación , Fármacos Hematológicos/uso terapéutico , alfa-Tocoferol/uso terapéutico , Síndrome de Radiación Aguda/metabolismo , Síndrome de Radiación Aguda/patología , Animales , Antioxidantes/farmacología , Caspasa 3/metabolismo , Ciclooxigenasa 2/metabolismo , Filgrastim/farmacología , Tracto Gastrointestinal/metabolismo , Tracto Gastrointestinal/patología , Fármacos Hematológicos/farmacología , Masculino , Ratones , Óxido Nítrico Sintasa de Tipo II/metabolismo , Proteína p53 Supresora de Tumor/metabolismo , Irradiación Corporal Total/efectos adversos , alfa-Tocoferol/farmacología

RESUMEN

TMCA (3,4,5-trimethoxycinnamic acid) ester and amide are privileged structural scaffolds in drug discovery which are widely distributed in natural products and consequently produced diverse therapeutically relevant pharmacological functions. Owing to the potential of TMCA ester and amide analogues as therapeutic agents, researches on chemical syntheses and modifications have been carried out to drug-like candidates with broad range of medicinal properties such as antitumor, antiviral, CNS (central nervous system) agents, antimicrobial, anti-inflammatory and hematologic agents for a long time. At the same time, SAR (structure-activity relationship) studies have draw greater attention among medicinal chemists, and many of the lead compounds were derived for various disease targets. However, there is an urgent need for the medicinal chemists to further exploit the precursor in developing chemical entities with promising bioactivity and druggability. This review concisely summarizes the synthesis and biological activity for TMCA ester and amide analogues. It also comprehensively reveals the relationship of significant biological activities along with SAR studies.

Asunto(s)

Cinamatos/farmacología , Antibacterianos/química , Antibacterianos/farmacología , Antiinflamatorios no Esteroideos/química , Antiinflamatorios no Esteroideos/farmacología , Antineoplásicos/química , Antineoplásicos/farmacología , Antivirales/química , Antivirales/farmacología , Fármacos del Sistema Nervioso Central/química , Fármacos del Sistema Nervioso Central/farmacología , Cinamatos/química , Fármacos Hematológicos/química , Fármacos Hematológicos/farmacología , Estructura Molecular

RESUMEN

Cytochrome P450 3A (CYP3A) is the most relevant drug-metabolizing enzyme in human beings involved in the elimination of about 50% of the marketed drugs. Comprehensive in vivo data of CYP3A activity in palliative patients with haematological diseases are missing. Therefore, CYP3A activity was determined under real-life clinical conditions in patients to gain knowledge about dose adjustments for supportive therapies and symptom management in haematology. The single-arm, prospective trial obtained a 4-hours pharmacokinetic profile of midazolam after oral administration of a microdose as marker substance from each enrolled patient. Plasma concentrations of midazolam and its primary metabolite 1'-hydroxy-midazolam were quantified by mass spectrometry techniques. CYP3A activity was calculated as partial metabolic clearance from an established limited sampling area under the curve. All other drugs taken by the participating patients were considered as well as recent laboratory test results and the patients' diagnoses. Partial metabolic clearance of midazolam in patients with haematological diseases was highly variable (36.9 ± 52.7 L/h). In comparison with the CYP3A activity of healthy individuals, this was a highly significant 30% reduction of activity (P < 0.0001). Dosing of major CYP3A substrate drugs needs to be reduced in palliative patients with haematological diseases, otherwise escalation of debilitating symptoms due to drug interactions might occur.

Asunto(s)

Citocromo P-450 CYP3A/metabolismo , Fármacos Hematológicos/farmacología , Enfermedades Hematológicas/tratamiento farmacológico , Midazolam/farmacocinética , Cuidados Paliativos/métodos , Administración Oral , Adulto , Anciano , Área Bajo la Curva , Variación Biológica Poblacional , Estudios de Casos y Controles , Interacciones Farmacológicas , Voluntarios Sanos , Fármacos Hematológicos/uso terapéutico , Enfermedades Hematológicas/sangre , Humanos , Tasa de Depuración Metabólica , Midazolam/administración & dosificación , Persona de Mediana Edad , Estudios Prospectivos